Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Tan, Gene S ^a   Leon, Paul E ^a   Albrecht, Randy A ^a   Margine, Irina ^a   Hirsh, Ariana ^a   Bahl, Justin ^b   Krammer, Florian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HEMAGGLUTININ; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VACCINE; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEMAGGLUTINATION INHIBITION; INFLUENZA A VIRUS (H7N9); LD50; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; TRANSACTIVATION ASSAY; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; HUMAN; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84964864966     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005578     Document Type: Article

References (50)

1. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888–97. doi: 10.1056/NEJMoa130445923577628
2. Qin Y, Horby PW, Tsang TK, Chen E, Gao L, Ou J, et al. Differences in the Epidemiology of Human Cases of Avian Influenza A(H7N9) and A(H5N1) Viruses Infection. Clin Infect Dis. 2015.
3. Ramos I, Krammer F, Hai R, Aguilera D, Bernal-Rubio D, Steel J, et al. H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids. J Gen Virol. 2013;94(Pt Pt_11):2417–23. doi: 10.1099/vir.0.056184-023950563
4. Xu R, de Vries RP, Zhu X, Nycholat CM, McBride R, Yu W, et al. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science. 2013;342(6163):1230–5. doi: 10.1126/science.124376124311689
5. Hu J, Zhu Y, Zhao B, Li J, Liu L, Gu K, et al. Limited human-to-human transmission of avian influenza A(H7N9) virus, Shanghai, China, March to April 2013. Euro Surveill. 2014;19(25).
6. Shi Y, Zhang W, Wang F, Qi J, Wu Y, Song H, et al. Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science. 2013;342(6155):243–7. doi: 10.1126/science.124291724009358
7. Yang Y, Zhang Y, Fang L, Halloran ME, Ma M, Liang S, et al. Household transmissibility of avian influenza A (H7N9) virus, China, February to May 2013 and October 2013 to March 2014. Euro Surveill. 2015;20(10):21056. 25788253
8. Zhu Y, Qi X, Cui L, Zhou M, Wang H, Human co-infection with novel avian influenza A H7N9 and influenza A H3N2 viruses in Jiangsu province, China. Lancet. 2013;381(9883):2134. doi: 10.1016/S0140-6736(13)61135-623769236
9. Li J, Kou Y, Yu X, Sun Y, Zhou Y, Pu X, et al. Human co-infection with avian and seasonal influenza viruses, China. Emerg Infect Dis. 2014;20(11):1953–5. doi: 10.3201/eid2011.14089725340661
10. Zhang W, Zhu D, Tian D, Xu L, Zhu Z, Teng Z, et al. Co-infection with Avian (H7N9) and Pandemic (H1N1) 2009 Influenza Viruses, China. Emerg Infect Dis. 2015;21(4):715–8. doi: 10.3201/eid2104.14156025811107
11. Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-Thasan N, A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med. 2014;6(234):234ra55. doi: 10.1126/scitranslmed.300876124786323
12. Fries LF, Smith GE, Glenn GM, A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013;369(26):2564–6.
13. Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Anderson E, Rouphael N, et al. Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant: A Randomized Clinical Trial. JAMA. 2014;312(14):1409–19. doi: 10.1001/jama.2014.1285425291577
14. Krammer F, Jul-Larsen A, Margine I, Hirsh A, Sjursen H, Zambon M, et al. An H7N1 Influenza Virus Vaccine Induces Broadly Reactive Antibody Responses against H7N9 in Humans. Clin Vaccine Immunol. 2014;21(8):1153–63. doi: 10.1128/CVI.00272-1424943383
15. Halliley JL, Khurana S, Krammer F, Fitzgerald T, Coyle EM, Chung KY, et al. High Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine after Priming with Live Attenuated Influenza Vaccine. J Infect Dis. 2015.
16. Couch RB, Patel SM, Wade-Bowers CL, Niño D, A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012;7(12):e49704. doi: 10.1371/journal.pone.004970423239968
17. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009;27(13):1889–97. doi: 10.1016/j.vaccine.2009.01.11619368768
18. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015;314(3):237–46. doi: 10.1001/jama.2015.791626197184
19. Klausberger M, Wilde M, Palmberger D, Hai R, Albrecht RA, Margine I, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine. 2014;32(3):355–62. doi: 10.1016/j.vaccine.2013.11.03624262313
20. Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, et al. Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol. 2014;88(8):3976–85. doi: 10.1128/JVI.03095-1324453375
21. Rudenko L, Isakova-Sivak I, Donina S, H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine. 2013;31(42):4702–5. doi: 10.1016/j.vaccine.2013.08.04023988294
22. Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013;31(40):4305–13. doi: 10.1016/j.vaccine.2013.07.04323891795
23. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P, A pan-h1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012;86(11):6179–88. doi: 10.1128/JVI.00469-1222491456
24. Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza a virus hemagglutinin. J Virol. 2014;88(23):13580–92. doi: 10.1128/JVI.02289-1425210195
25. Magadán JG, Khurana S, Das SR, Frank GM, Stevens J, Golding H, et al. Influenza A virus hemagglutinin trimerization completes monomer folding and antigenicity. J Virol. 2013;87(17):9742–53. doi: 10.1128/JVI.00471-1323824811
26. Baudino L, Shinohara Y, Nimmerjahn F, Furukawa J, Nakata M, Martínez-Soria E, et al. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 2008;181(9):6664–9. 18941257
27. Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, et al. Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo-Controlled, Randomized Double-Blind Phase I Study of Live Attenuated H7N3Influenza Vaccine. PLoS One. 2014;9(2):e87962. doi: 10.1371/journal.pone.008796224533064
28. Chen A, McKinley SA, Wang S, Shi F, Mucha PJ, Forest MG, et al. Transient antibody-mucin interactions produce a dynamic molecular shield against viral invasion. Biophys J. 2014;106(9):2028–36. doi: 10.1016/j.bpj.2014.02.03824806935
29. Wessler T, Chen A, McKinley SA, Cone R, Forest G, Lai SK, Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in Mucus. ACS Infect Dis. 2016;2(1):82–92. 26771004
30. Nadesalingam J, Reid KB, Palaniyar N, Collectin surfactant protein D binds antibodies and interlinks innate and adaptive immune systems. FEBS Lett. 2005;579(20):4449–53. 16061223
31. Dilillo DJ, Tan GS, Palese P, Ravetch JV, Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014;20(2):143–51. doi: 10.1038/nm.344324412922
32. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ, Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol. 2013;87(10):5512–22. doi: 10.1128/JVI.03030-1223468501
33. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101(5):1356–61. 14745020
34. Lopez-Martinez I, Balish A, Barrera-Badillo G, Jones J, Nuñez-García TE, Jang Y, et al. Highly pathogenic avian influenza A(H7N3) virus in poultry workers, Mexico, 2012. Emerg Infect Dis. 2013;19(9):1531–4. doi: 10.3201/eid1909.13008723965808
35. Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004;10(12):2196–9. 15663860
36. Highly pathogenic H7N7 avian influenza confirmed in Lancashire. Vet Rec. 2015;177(3):57–8.
37. Goff PH, Krammer F, Hai R, Seibert CW, Margine I, García-Sastre A, et al. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J Virol. 2013;87(14):8235–40. doi: 10.1128/JVI.01085-1323698299
38. Babu TM, Levine M, Fitzgerald T, Luke C, Sangster MY, Jin H, et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine. 2014;32(50):6798–804. doi: 10.1016/j.vaccine.2014.09.07025446831
39. Mallett CP, Beaulieu E, Joly MH, Baras B, Lu X, Liu F, et al. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes. Vaccine. 2015;33(32):3784–7. doi: 10.1016/j.vaccine.2015.06.05326100923
40. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R, Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol. 2010;45(3):226–34. doi: 10.1007/s12033-010-9268-320300881
41. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P, A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One. 2012;7(8):e43603. doi: 10.1371/journal.pone.004360322928001
42. Margine I, Palese P, Krammer F, Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System. J Vis Exp. 2013;(81).
43. Margine I, Martinez-Gil L, Chou YY, Krammer F, Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One. 2012;7(12):e51559. doi: 10.1371/journal.pone.005155923236516
44. Halliley JL, Khurana S, Krammer F, Fitzgerald T, Coyle EM, Chung KY, et al. High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. J Infect Dis. 2015;212(8):1270–8. doi: 10.1093/infdis/jiv21025838266
45. Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F, Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio. 2016;7(1).
46. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12(6):682–7. 16715088
47. Edgar RC, MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32(5):1792–7. 15034147
48. Lina B, Bouscambert M, Enouf V, Rousset D, Valette M, van der Werf S, S-OtrH3N2 viruses: use of sequence data for description of the molecular characteristics of the viruses and their relatedness to previously circulating H3N2 human viruses. Euro Surveill. 2011;16(50):20039. 22221493
49. Schmeisser F, Vasudevan A, Verma S, Wang W, Alvarado E, Weiss C, et al. Antibodies to antigenic site A of influenza H7 hemagglutinin provide protection against H7N9 challenge. PLoS One. 2015;10(1):e0117108. doi: 10.1371/journal.pone.011710825629172
50. Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest. 2015;125(3):1255–68. doi: 10.1172/JCI7437425689254